Notice convening an Extraordinary General Meeting of Novo Nordisk A/S Bagsværd, Denmark, 21 October 2025 – Further to company announcement no. 28 issued today, an Extraordinary General Meeting of Novo Nordisk A/S is called to elect new members to the Board of Directors in accordance with the meeting agenda and proposals included in the enclosed meeting notice. The Extraordinary General Meeting will be held on Friday 14 November 2025 at 14:00 (CET). The Extraordinary General Meeting will be held as a fully electronic general meeting. Accordingly, participation in the meeting will take plac...
Novo Nordisk announces an Extraordinary General Meeting to be convened to elect new members of the Board of Directors Bagsværd, Denmark, 21 October 2025 - Novo Nordisk today announced that the Board of Directors have decided to convene an Extraordinary General Meeting to elect new members of the Board of Directors of Novo Nordisk. “Following dialogue with the Novo Nordisk Foundation regarding the future composition of the Board of Directors, it has not been possible to reach a common understanding. The Board proposed a renewal focusing on addition of select, new competencies while also mai...
Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart (OMS906) Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare Disease portfolioOmeros is eligible to receive 340 million US dollars in upfront and near-term milestone payments, up to a total of 2.1 billion dollars including potential development and commercial milestones, plus tiered royalties on net sales Bagsværd, Denmark and Seattle, US, 15 October 2025 – Novo Nordisk and Omeros Corporation (...
JDE Peet’s unveils transformed Innovation Laboratory in Utrecht to accelerate next-generation coffee breakthroughs PRESS RELEASE Amsterdam, October 14, 2025 JDE Peet’s (EURONEXT: JDEP) today announces the opening of its fully revamped modular Innovation Laboratory in Utrecht, the Netherlands, to accelerate next-generation coffee breakthroughs.The new facility underscores the company’s commitment to the rapid scaling of customer-led innovations, as well as the strategic importance of JDE Peet’s global R&D centre in Utrecht. The Innovation Lab’s pioneering, modular setup enables ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.